Study Investigating the Safety and Tolerability of Multiple Doses of PF-02545920 in Subjects With Schizophrenia

Inclusion Criteria: * Subjects with DSM-IV diagnosis of schizophrenia or schizo-affective disorder for whom antipsychotic monotherapy is indicated. * Subjects must be free from an acute exacerbation of psychosis for at least 3 months prior to screening. * Current Clinical Global Impression (CGI) of Severity of Illness score ≤ 3. Exclusion Criteria: * Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing). * Evidence or history of a primary DSM-IV axis I diagnosis other than schizophrenia or schizoaffective disorder. * Any condition possibly affecting drug absorption (e.g., gastrectomy).